English
Back
Open Account
中康控股公佈配售結果，你中籤了嗎？
牛牛新股君
joined discussion · Jul 11, 2022 07:46

New Share Pricing | China Hong Kong Holdings wins 2.21 times bid, priced at HK$5.36 per share

Futu News July 11, This Week$SINOHEALTH TECH (02361.HK)$The announcement was made that the company issued 7500 million shares at a price of HK$5.36 per share and 500 shares per share and is expected to be listed on July 12.

During the IPO period, Kang Holdings acquired a 2.21 multiplier purchase and the final number of shares allocated to the public offering was 750 million shares, representing approximately 10% of the total shares sold (prior to the exercise of any superannuation rights). A total of 4352 valid applications were received, and the participation rate was 50.02%.
Outside of this, the Company has sold a superannuation, with a maximum target of 6750 shares, equivalent to about 90% of the sold shares (before any superannuation is implemented. The Futu Constraint Sort is related to the following:
Futu News July 11, This Week$SINOHEALTH TECH (02361.HK)$The announcement was made that the company issued 7500 million shares at a price of HK$5.36 per share and 500 shares per share and is expected to be listed on July 12. During the IPO period, Kang Holdings acquired a 2.21 multiplier purchase and the final number of shares allocated to the public offering was 750 million shares, representing approximately 10% of the total shares sold (prior to the exercise of any superannuation rights). A total of 4352 valid applications were received, and the participation rate was 50.02%. Outside of this, the Company has sold a superannuation, with a maximum target of 6750 shares, equivalent to about 90% of the sold shares (before any superannuation is implemented. The Futu Constraint Sort is related to the following: CITIC HOLDINGS PRIMARILY PROVIDES HEALTH INSIGHT SOLUTIONS TO ADDRESS THE SALES AND MARKETING NEEDS OF MEDICAL PRODUCT MANUFACTURER CUSTOMERS. These solutions are mainly based on the company's retail data, while retail data makes up the bulk of the company's healthy big data. Since 2008, the company has been committed to driving the digital transformation of China's health industry. Driven by big data and technology, the company has been developing comprehensive health big data solutions for health industry participants, primarily providing market-driven end-to-end solutions for the sales and marketing functions of medical product manufacturer customers. and products. The company is a leader in the medical products and channels division. According to Airy Consulting's report, according to 2021...
CITIC HOLDINGS PRIMARILY PROVIDES HEALTH INSIGHT SOLUTIONS TO ADDRESS THE SALES AND MARKETING NEEDS OF MEDICAL PRODUCT MANUFACTURER CUSTOMERS. These solutions are mainly based on the company's retail data, while retail data makes up the bulk of the company's healthy big data.
Since 2008, the company has been committed to driving the digital transformation of China's health industry. Driven by big data and technology, the company has been developing comprehensive health big data solutions for health industry participants, primarily providing market-driven end-to-end solutions for the sales and marketing functions of medical product manufacturer customers. and products.
The company is a leader in the medical products and channels division. According to Airi Consulting, the number of top medical product manufacturers served in 2020 (based on Torreya and the 2020 list of top medical product manufacturers based on Torreya and Pharma Network's 2020 list of top medical product manufacturers) and enterprise-class customer numbers for China Health Insights Solutions, according to an Airi Consulting report, based on the number of top medical product manufacturers and enterprise-class customers Words ranked first.
In terms of financial condition, the Company's revenue in 2019—2021 was RMB 1.78, 2.02 yuan and RMB 3.24, with a compound growth rate of 34.92% over the three years, and net profit was HK$5437.9 million, RMB6532.9 million and RMB7197.8 million, respectively. The net interest rate was 30.6%, 32.3% and 22.2%, respectively.
Futu News July 11, This Week$SINOHEALTH TECH (02361.HK)$The announcement was made that the company issued 7500 million shares at a price of HK$5.36 per share and 500 shares per share and is expected to be listed on July 12. During the IPO period, Kang Holdings acquired a 2.21 multiplier purchase and the final number of shares allocated to the public offering was 750 million shares, representing approximately 10% of the total shares sold (prior to the exercise of any superannuation rights). A total of 4352 valid applications were received, and the participation rate was 50.02%. Outside of this, the Company has sold a superannuation, with a maximum target of 6750 shares, equivalent to about 90% of the sold shares (before any superannuation is implemented. The Futu Constraint Sort is related to the following: CITIC HOLDINGS PRIMARILY PROVIDES HEALTH INSIGHT SOLUTIONS TO ADDRESS THE SALES AND MARKETING NEEDS OF MEDICAL PRODUCT MANUFACTURER CUSTOMERS. These solutions are mainly based on the company's retail data, while retail data makes up the bulk of the company's healthy big data. Since 2008, the company has been committed to driving the digital transformation of China's health industry. Driven by big data and technology, the company has been developing comprehensive health big data solutions for health industry participants, primarily providing market-driven end-to-end solutions for the sales and marketing functions of medical product manufacturer customers. and products. The company is a leader in the medical products and channels division. According to Airy Consulting's report, according to 2021...
In terms of industry, according to data from Airi Consulting, the Chinese Health Insights Solutions market will grow at 39.2% in the combined year from 2021 to 2026, and the market size will reach RMB 1,303 by 2026.
Futu News July 11, This Week$SINOHEALTH TECH (02361.HK)$The announcement was made that the company issued 7500 million shares at a price of HK$5.36 per share and 500 shares per share and is expected to be listed on July 12. During the IPO period, Kang Holdings acquired a 2.21 multiplier purchase and the final number of shares allocated to the public offering was 750 million shares, representing approximately 10% of the total shares sold (prior to the exercise of any superannuation rights). A total of 4352 valid applications were received, and the participation rate was 50.02%. Outside of this, the Company has sold a superannuation, with a maximum target of 6750 shares, equivalent to about 90% of the sold shares (before any superannuation is implemented. The Futu Constraint Sort is related to the following: CITIC HOLDINGS PRIMARILY PROVIDES HEALTH INSIGHT SOLUTIONS TO ADDRESS THE SALES AND MARKETING NEEDS OF MEDICAL PRODUCT MANUFACTURER CUSTOMERS. These solutions are mainly based on the company's retail data, while retail data makes up the bulk of the company's healthy big data. Since 2008, the company has been committed to driving the digital transformation of China's health industry. Driven by big data and technology, the company has been developing comprehensive health big data solutions for health industry participants, primarily providing market-driven end-to-end solutions for the sales and marketing functions of medical product manufacturer customers. and products. The company is a leader in the medical products and channels division. According to Airy Consulting's report, according to 2021...
From 2021 to 2026, the combined growth rate of China's medical products and channel insight solutions market will be 49.4%, and the market size will now reach RMB611.
Futu News July 11, This Week$SINOHEALTH TECH (02361.HK)$The announcement was made that the company issued 7500 million shares at a price of HK$5.36 per share and 500 shares per share and is expected to be listed on July 12. During the IPO period, Kang Holdings acquired a 2.21 multiplier purchase and the final number of shares allocated to the public offering was 750 million shares, representing approximately 10% of the total shares sold (prior to the exercise of any superannuation rights). A total of 4352 valid applications were received, and the participation rate was 50.02%. Outside of this, the Company has sold a superannuation, with a maximum target of 6750 shares, equivalent to about 90% of the sold shares (before any superannuation is implemented. The Futu Constraint Sort is related to the following: CITIC HOLDINGS PRIMARILY PROVIDES HEALTH INSIGHT SOLUTIONS TO ADDRESS THE SALES AND MARKETING NEEDS OF MEDICAL PRODUCT MANUFACTURER CUSTOMERS. These solutions are mainly based on the company's retail data, while retail data makes up the bulk of the company's healthy big data. Since 2008, the company has been committed to driving the digital transformation of China's health industry. Driven by big data and technology, the company has been developing comprehensive health big data solutions for health industry participants, primarily providing market-driven end-to-end solutions for the sales and marketing functions of medical product manufacturer customers. and products. The company is a leader in the medical products and channels division. According to Airy Consulting's report, according to 2021...
Related Reading:Reading at a Glance | Zhongkang Holdings, a Leader in Delivering Healthy Big Data Solutions to Enterprise-Class Clients
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Heart
1
Angry
1
Thumbs Up
4
124K Views
Report
Comment (1)
Write a Comment...
1
6
10